Form 4: Lilly Endowment Sells $152M Eli Lilly Shares

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 142,307 shares of common stock for approximately $152 million through pre-arranged trading plans.

Summary

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), sold a total of 142,307 shares of common stock on November 24, 2025.
• The sales were executed in multiple transactions at weighted average prices ranging from $1,068.175 to $1,073.597 per share.
• The total value of the shares sold is approximately $152.2 million.
• Following these transactions, Lilly Endowment Inc. beneficially owns 92,359,671 shares of Eli Lilly & Co. common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) trading plan, indicating a pre-scheduled sale.

Sentiment

Score: 5

Explanation: Neutral to slightly negative. While a large sale by a significant owner can be perceived negatively, the pre-planned nature via a 10b5-1 plan mitigates concerns of immediate negative sentiment or insider reaction to new information. It likely represents portfolio rebalancing.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, suggesting a pre-planned portfolio adjustment rather than a reaction to new negative information.

Negatives

• A significant sale by a 10% owner could be perceived negatively by some investors, potentially signaling a reduction in conviction or a move to diversify.

Future Outlook

Not applicable. This Form 4 filing details past transactions and does not provide forward-looking statements or guidance.

Management Comments

• The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,068.00 to $1,068.99, inclusive.
• The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), and (6) to this Form 4.

Industry Context

This transaction represents an internal ownership change by a significant shareholder and does not directly reflect broader industry trends. However, large sales by major holders in a high-performing pharmaceutical stock like Eli Lilly are often observed for market sentiment.

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., sold shares of the company's common stock. This constitutes a transaction by a related party.

Stakeholder Impact

• Shareholders: The sale by a significant 10% owner could lead to short-term negative sentiment or increased selling pressure, though the 10b5-1 plan suggests it's not based on new adverse information.

Key Dates

Recommendation

The sale by Lilly Endowment Inc. is a significant transaction in terms of value, but its execution under a Rule 10b5-1 plan suggests a pre-determined portfolio adjustment rather than a reaction to new, adverse company-specific information. Eli Lilly & Co. remains a strong company, and this sale by a long-term holder is likely for diversification or rebalancing purposes. Investors should monitor future insider activity but not overreact to this planned sale.

Keywords

Eli Lilly, LLY, Lilly Endowment, insider trading, Form 4, beneficial ownership, stock sale, 10b5-1 plan, pharmaceutical, healthcare